Mln8237

MG-132 (#HY-13259), Cycloheximide (#HY-12320), MLN8237 (#HY-10971), and SZL P1-41(#HY-100237) were purchased from MedChemExpress, and dissolved in dimethyl sulfoxide (DMSO) (#N182, Amresco) and stored at −20 °C.

The human neuroblastoma cell lines IMR-32, SK-N-SH, SH-SY5Y, and SK-N-BE (2) and human embryonic kidney 293T cells were obtained from the American Type Culture Collection (Manassas, VA, United States). IMR-32, SK-N-SH, and 293T cells were cultured in Dulbecco’s modified Eagle medium (DMEM, Gibco, Carlsbad, CA, United States) containing 10% fetal bovine serum (FBS, Gibco) at 37°C with 5% CO₂. SH-SY5Y and SK-N-BE (2) cells were cultured in minimum essential medium/F12 medium (Gibco) at 37°C and 5% CO₂ until reaching 70% cell density. The neuroblastoma cells were inoculated at 3 × 10⁵ cells/mL in six-well plates, with 0.5 μM doxorubicin (DOX, MedChemExpress, Monmouth Junction, NJ, United States) and 2 μM MLN8237 (MedChemExpress) added after 24 h. Two control groups [treated with complete medium and dimethyl sulfoxide (DMSO)] were established and incubated for 72 h for the cellular senescence model.

The human neuroblastoma cell lines IMR32, SK-N-BE, LAN-1, SK-N-SH and hepatocarcinoma cell line HepG2, and glioma cell line U373 were obtained from American Type Culture Collection (ATCC). All cell lines were cultured in DMEM medium supplemented with 10% fetal bovine serum and the antibiotics penicillin and streptomycin. The Aurora A kinase inhibitor MLN8237 (Alisertib, HY-10971) was purchased from Medchem Express (MCE). All other reagents were commercially available.